Magainin-2 [G3,18K; K4,14Dap; F5W; A15K; E19K; M21Nle]

General Information


DRACP ID  DRACP01970

Peptide Name   Magainin-2 [G3,18K; K4,14Dap; F5W; A15K; E19K; M21Nle]

Sequence  GIKXWLHSAKKFGXKFVKKIXNS

Sequence Length  23

UniProt ID  P11006 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
PANC-1 Pancreatic ductal adenocarcinoma Carcinoma EC50=14.7±0.6 µM(pH=7.4) WST-1 assay 24 h 1

Hemolytic Activity  Human kidney-derived GM cells: EC50=25.9±0.6 µM(pH=6); EC50=50.3±0.9 µM(pH=7.4)

Normal (non-cancerous) Cytotoxicity  HEK293: EC50=27.2±3.1 µM(pH=7.4)

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  X(4/14)=Dap; X(21)=Nle

Chiral  L



Physicochemical Information


Formula  C111H172N30O21

Absent amino acids  CDEMPQRTY

Common amino acids  K

Mass  298536

Pl  11.5

Basic residues  7

Acidic residues  0

Hydrophobic residues  8

Net charge  7

Boman Index  -2062

Hydrophobicity  -39.13

Aliphatic Index  67.83

Half Life 
  /

Extinction Coefficient cystines  5500

Absorbance 280nm  250

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 31161686

Title  Endowment of pH responsivity to anticancer peptides by introducing 2,3-diaminopropionic acid residues

Doi 10.1002/cbic.201900226

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_13419

DRACP is developed by Dr.Zheng's team.